Genomic Valley — 360° view

Genomic Valley, a company in the Biotechnology industry, reported revenue of ₹0.04 crore and net profit of ₹0.01 crore for the June 2026 quarter.

Genomic Valley (BSE: GVBL) closed at ₹44.75 on 20 Nov 2026, up 47.4% over the past year. Its market capitalisation is ₹14 crore.

Share price
₹44.75 (20 Nov 2026)
Market cap
₹14 Cr (20 Nov 2026)
Revenue
₹0 Cr (June 2026 quarter)
Net profit
₹0 Cr (June 2026 quarter)
ROCE
1.02% (FY26)
ROE
0.77% (FY26)
Book value
₹12.8 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹61.37 / ₹20.10 (20 Nov 2026)
1-year return
47.4% (to 20 Nov 2026)
Sector
Healthcare
Industry
Biotechnology
Symbol
BSE: GVBL

Incorporated in 2001, Genomic Valley Biotech Ltd is in the business of Horticultural and Agricultural products, and is also adding activities in Human Genomic

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.